Junshi plans filings after toripalimab hits target in upper throat cancerChina’s Junshi Biosciences has said it plans filings for a new cancer immunotherapy after its toripalimab outperformed standard Share XJunshi plans filings after toripalimab hits target in upper throat cancerhttps://pharmaphorum.com/news/junshi-plans-filings-after-toripalimab-hits-target-in-upper-throat-cancer/